Tonix Pharmaceuticals to Present at Two Upcoming Investor
TNX-102 SL, a non-opioid analgesic, showed significant pain reduction over placebo in a Phase 3 trial and positive effects across secondary endpoints. Tonix Pharmaceuticals plans to submit an NDA to the FDA in 2024 for fibromyalgia treatment. The company also develops treatments for Long COVID, cocaine intoxication, and other diseases, with several products in clinical trials.
Reference News
TNX-102 SL, a non-opioid analgesic, showed significant pain reduction over placebo in a Phase 3 trial and positive effects across secondary endpoints. Tonix Pharmaceuticals plans to submit an NDA to the FDA in 2024 for fibromyalgia treatment. The company also develops treatments for Long COVID, cocaine intoxication, and other diseases, with several products in clinical trials.